Pharmacokinetic behaviour of antithrombin III following intravenous infusion in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 3, 2002, Pages 187-193

  Marzo, Antonio ^a   Ceppi Monti, Nunzia ^a   Giusti, Andrea ^a   Abbiati, Gianalfredo ^a   Parenti, Maddalena ^a  

^a Inst for Pharmaco/Anal Stud SA   (Switzerland)

Author keywords

Antithrombin, antithrombin III, antithrombin III antigen, functional antithrombin III, healthy volunteers, nanofiltration purification, pharmacokinetics; CAS 52014 67 2

Indexed keywords

ANTITHROMBIN III;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MALE; NANOFILTRATION; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PROTHROMBIN TIME;

EID: 0036199178     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299878     Document Type: Article

References (10)

1. Evaluation of the safety, recovery, half-life and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency
2. Role of antithrombin III in coagulation disorders: State of the art review
3. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin
4. Swiss regulations for controlling clinical trials
5. Pharmacokinetics of endogenous substances: Some problems and some solutions
6. Bioequivalence of endogenous substances facing homeostatic equilibria: An example with potassium